{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:24:40Z","timestamp":1787567080499,"version":"build-2736575974"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic inflammatory disorder of the airways characterized by substantial morbidity, disability, and mortality. It poses a significant global public health burden. Conventional therapies for COPD, which mainly rely on bronchodilators and inhaled corticosteroids, effectively relieve symptoms and reduce exacerbation frequency in patients. However, their clinical utility is limited by safety concerns and heterogeneous treatment responses across disease phenotypes. Moreover, these therapeutic approaches cannot halt or reverse disease progression. With increasing understanding of the complex molecular and cellular mechanisms underlying COPD pathogenesis, therapeutic approaches are evolving from conventional symptom-oriented management toward precision medicine and mechanism-based targeted interventions. This review systematically summarizes recent advances in emerging targeted therapies for COPD, including monoclonal antibodies directed against key inflammatory pathways, small-molecule modulators targeting core pathogenic mechanisms, and stem cell-based therapies. By selectively modulating critical processes involved in chronic inflammation, tissue injury, and airway remodeling, these novel therapeutic strategies offer promising therapeutic opportunities, particularly for patients with corticosteroid resistance and frequent exacerbations.<\/jats:p>","DOI":"10.3389\/fphar.2026.1911892","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:43:27Z","timestamp":1787561007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging targeted therapies for chronic obstructive pulmonary disease: from symptom control to precision medicine"],"prefix":"10.3389","volume":"17","author":[{"given":"Guangwei","family":"Chen","sequence":"first","affiliation":[{"name":"Pulmonology Department, Fangcheng County People\u2019s Hospital","place":["Nanyang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haishun","family":"Yang","sequence":"additional","affiliation":[{"name":"Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihang","family":"Sun","sequence":"additional","affiliation":[{"name":"Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Shen","sequence":"additional","affiliation":[{"name":"Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ma","sequence":"additional","affiliation":[{"name":"Pulmonology Department, Fangcheng County People\u2019s Hospital","place":["Nanyang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Qin","sequence":"additional","affiliation":[{"name":"Pulmonology Department, Fangcheng County People\u2019s Hospital","place":["Nanyang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Henan Provincial Research Center of Engineering Technology for Nuclear Protein Medical Detection, School of Medicine and Health Sciences, Zhengzhou Health College","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Henan University","place":["Kaifeng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Huaihe Hospital of Henan University, Henan University","place":["Kaifeng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieshan","family":"Teng","sequence":"additional","affiliation":[{"name":"Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University","place":["Kaifeng, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichang","family":"Sun","sequence":"additional","affiliation":[{"name":"Pulmonology Department, Fangcheng County People\u2019s Hospital","place":["Nanyang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Henan Provincial Research Center of Engineering Technology for Nuclear Protein Medical Detection, School of Medicine and Health Sciences, Zhengzhou Health College","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"104318","DOI":"10.1016\/j.lpm.2025.104318","article-title":"Personalizing COPD care: phenotypes, endotypes, GETomics, the trajectome, syndemics and treatable traits","volume":"55","author":"Agusti","year":"2026","journal-title":"Presse Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2300239","DOI":"10.1183\/13993003.00239-2023","article-title":"Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"61","author":"Agust\u00ed","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/psp4.12565","article-title":"A physiologically based pharmacokinetic model to predict potential drug-drug interactions and inform dosing of acumapimod, an oral p38 MAPK inhibitor","volume":"10","author":"Agyemang","year":"2021","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12964-023-01337-4","article-title":"p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics","volume":"21","author":"Ahmadi","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0158-2","article-title":"IL-17A-associated IKK-\u03b1 signaling induced TSLP production in epithelial cells of COPD patients","volume":"50","author":"Anzalone","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1021\/acs.jmedchem.2c00115","article-title":"Design, synthesis, and biological characterization of inhaled p38\u03b1\/\u03b2 MAPK inhibitors for the treatment of lung inflammatory diseases","volume":"65","author":"Armani","year":"2022","journal-title":"J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/sctm.21-0024","article-title":"Transcriptional profiling of circulating mononuclear cells from patients with chronic obstructive pulmonary disease receiving mesenchymal stromal cell infusions","volume":"10","author":"Armitage","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"102075","DOI":"10.1016\/j.pupt.2021.102075","article-title":"Mesenchymal stromal cells-based therapy in a murine model of elastase-induced emphysema: Simvastatin as a potential adjuvant in cellular homing","volume":"70","author":"Arruda de Faria","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1164\/rccm.202407-1287RL","article-title":"Blood eosinophil count stability in chronic obstructive pulmonary disease and the eosinophilic exacerbator phenotype","volume":"211","author":"Baraldi","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"101544","DOI":"10.1016\/j.redox.2020.101544","article-title":"Oxidative stress-based therapeutics in COPD","volume":"33","author":"Barnes","year":"2020","journal-title":"Redox Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.molmed.2011.02.006","article-title":"NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease","volume":"17","author":"Boutten","year":"2011","journal-title":"Trends Mol. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"250110","DOI":"10.1183\/16000617.0110-2025","article-title":"A translational view of airway epithelial dysfunction in COPD","volume":"34","author":"Brightling","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1007\/s12325-020-01373-3","article-title":"Benefits of tiotropium\/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of the TONADO\u00ae and OTEMTO\u00ae studies","volume":"37","author":"Buhl","year":"2020","journal-title":"Adv. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"220144","DOI":"10.1183\/16000617.0144-2022","article-title":"Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD","volume":"32","author":"Calderon","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3390\/cells11111797","article-title":"Stem cell-based regenerative therapy and derived products in COPD: a systematic review and meta-analysis","volume":"11","author":"Calzetta","year":"2022","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00408-025-00844-0","article-title":"Emerging therapeutics in COPD: mapping innovation to treatable traits","volume":"203","author":"Cazzola","year":"2025","journal-title":"Lung"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2502323","DOI":"10.1183\/13993003.02323-2025","article-title":"Lung-targeted HGF mRNA restores alveolar structure in experimental emphysema","author":"Chen","year":"2026","journal-title":"Eur. Respir. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2639673","DOI":"10.1080\/19420862.2026.2639673","article-title":"Structures of clinical antibodies bound to IL-33 uncover two distinct epitopes underlying differential efficacy","volume":"18","author":"Chen","year":"2026","journal-title":"MAbs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8916570","DOI":"10.1155\/2017\/8916570","article-title":"Mesenchymal stem cell administration in patients with chronic obstructive pulmonary disease: state of the science","volume":"2017","author":"Cheng","year":"2017","journal-title":"Stem Cells Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4046\/trd.2025.0180","article-title":"Biologics in chronic obstructive pulmonary disease: current status and future prospects","volume":"89","author":"Choi","year":"2026","journal-title":"Tuberc. Respir. Dis. (Seoul)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/psp4.12037","article-title":"Population PK-PD model for tolerance evaluation to the p38 MAP kinase inhibitor BCT197","volume":"4","author":"De Buck","year":"2015","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"9825","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","volume":"13","author":"England","year":"2023","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"740803","DOI":"10.3389\/fphar.2021.740803","article-title":"Tanimilast, A novel inhaled Pde4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease","volume":"12","author":"Facchinetti","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12931-020-1292-7","article-title":"Oxidative stress and Nrf2 expression in peripheral blood mononuclear cells derived from COPD patients: an observational longitudinal study","volume":"21","author":"Fratta Pasini","year":"2020","journal-title":"Respir. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"103931","DOI":"10.1016\/j.redox.2025.103931","article-title":"Nrf2 signaling in chronic obstructive pulmonary disease: regulation of ferroptosis and therapeutic implications","volume":"88","author":"Gao","year":"2025","journal-title":"Redox Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.chest.2021.04.020","article-title":"Stem cell therapy for COPD: hope and exploitation","volume":"160","author":"Glassberg","year":"2021","journal-title":"Chest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2502244","DOI":"10.1183\/13993003.02244-2025","article-title":"Addressing the global challenges of COPD and asthma: a shared vision from the global initiative for chronic obstructive pulmonary disease (GOLD) and the global initiative for asthma (GINA)","volume":"67","author":"Halpin","year":"2026","journal-title":"Eur. Respir. J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1164\/rccm.202008-3328PP","article-title":"From GOLD 0 to Pre-COPD","volume":"203","author":"Han","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"C331","DOI":"10.1152\/ajpcell.00467.2023","article-title":"RTA 408 ameliorates diabetic cardiomyopathy by activating Nrf2 to regulate mitochondrial fission and fusion and inhibiting NF-\u03baB-mediated inflammation","volume":"326","author":"Hao","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/thoraxjnl-2020-214712","article-title":"Role of the IL-33\/ST2 axis in cigarette smoke-induced airways remodelling in chronic obstructive pulmonary disease","volume":"76","author":"Huang","year":"2021","journal-title":"Thorax"},{"key":"B34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/thorax-2024-222113","article-title":"Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease","volume":"80","author":"Ioannides","year":"2025","journal-title":"Thorax"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1384718","DOI":"10.3389\/fimmu.2024.1384718","article-title":"Designer umbilical cord-stem cells induce alveolar wall regeneration in pulmonary disease models","volume":"15","author":"Iwatake","year":"2024","journal-title":"Front. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1021\/jm5000529","article-title":"Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis","volume":"57","author":"Jiang","year":"2014","journal-title":"J. Med. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2015.02.011","article-title":"Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection","volume":"42","author":"Kearley","year":"2015","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","first-page":"100042","DOI":"10.1016\/j.pharmr.2025.100042","article-title":"Cyclic nucleotide phosphodiesterases as drug targets","volume":"77","author":"Kelly","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12931-025-03360-0","article-title":"Safety and tolerability of astegolimab, an anti-ST2 monoclonal antibody: a narrative review","volume":"26","author":"Kelsen","year":"2025","journal-title":"Respir. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"38207","DOI":"10.1038\/srep38207","article-title":"Human mesenchymal stromal cells exert HGF dependent cytoprotective effects in a human relevant pre-clinical model of COPD","volume":"6","author":"Kennelly","year":"2016","journal-title":"Sci. Rep."},{"key":"B41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/B978-0-323-90871-9.00009-7","article-title":"Chapter 11 - Drug screening and high throughput in three-dimensional lung models","volume-title":"3D Lung Models for Regenerating Lung Tissue","author":"Kistemaker","year":"2022"},{"key":"B42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12931-023-02314-8","article-title":"Gene expression profiles in mesenchymal stromal cells from bone marrow, adipose tissue and lung tissue of COPD patients and controls","volume":"24","author":"Kruk","year":"2023","journal-title":"Respir. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13287-024-03940-9","article-title":"Stem cell therapies for chronic obstructive pulmonary disease: mesenchymal stem cells as a promising treatment option","volume":"15","author":"Lai","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8906","DOI":"10.3390\/ijms23168906","article-title":"Reduction of emphysema severity by human umbilical cord-derived mesenchymal stem cells in mice","volume":"23","author":"Laiman","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"154739","DOI":"10.1016\/j.cyto.2019.154739","article-title":"The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients","volume":"123","author":"Lea","year":"2019","journal-title":"Cytokine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","article-title":"Shattering barriers toward clinically meaningful MSC therapies","volume":"6","author":"Levy","year":"2020","journal-title":"Sci. Adv."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s10787-022-00967-3","article-title":"COPD lung studies of Nrf2 expression and the effects of Nrf2 activators","volume":"30","author":"Li","year":"2022","journal-title":"Inflammopharmacology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"22434","DOI":"10.1039\/d5cp01138h","article-title":"Hydrophobic interaction-driven binding of ensifentrine stabilizes PDE3A: insights from X-ray crystallography and molecular dynamics","volume":"27","author":"Li","year":"2025","journal-title":"Phys. Chem. Chem. Phys."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"101266","DOI":"10.1016\/j.redox.2019.101266","article-title":"CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-\u03baB activation","volume":"26","author":"Lu","year":"2019","journal-title":"Redox Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1007\/s12325-025-03231-6","article-title":"Effectiveness and safety of tezepelumab in a diverse population of US patients with severe asthma: initial results of the PASSAGE study","volume":"42","author":"Lugogo","year":"2025","journal-title":"Adv. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"aamag225","DOI":"10.1093\/ajrccm\/aamag225","article-title":"Tezepelumab in real-world U.S. patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study","author":"Lugogo","year":"2026","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(11)61047-7","article-title":"The future of chronic obstructive pulmonary disease treatment--difficulties of and barriers to drug development","volume":"378","author":"Martinez","year":"2011","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial","volume":"385","author":"Martinez","year":"2015","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12931-020-01388-y","article-title":"Benefits of glycopyrrolate\/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies","volume":"21","author":"Martinez","year":"2020","journal-title":"Respir. Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1343941","DOI":"10.3389\/fphar.2024.1343941","article-title":"CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder","volume":"15","author":"Martucci","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/17476348.2023.2196015","article-title":"Mesenchymal stromal cell therapy for chronic lung diseases: experimental and clinical evidence","volume":"17","author":"Melo","year":"2023","journal-title":"Expert Rev. Respir. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2014.01.013","article-title":"MSC-based product characterization for clinical trials: an FDA perspective","volume":"14","author":"Mendicino","year":"2014","journal-title":"Cell Stem Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1124\/jpet.114.220541","article-title":"CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration","volume":"352","author":"Moretto","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.2147\/COPD.S475281","article-title":"In vivo and in vitro models of PM2.5 induced COPD: focus on the role of RTA-408","volume":"19","author":"Niu","year":"2024","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(26)00637-9","article-title":"Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials","volume":"407","author":"Papi","year":"2026","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2147\/DDDT.S300988","article-title":"Role of p38 mitogen-activated protein kinase in asthma and COPD: pathogenic aspects and potential targeted therapies","volume":"15","author":"Pelaia","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e0122942","DOI":"10.1371\/journal.pone.0122942","article-title":"RTA 408, A novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity","volume":"10","author":"Probst","year":"2015","journal-title":"PLoS One"},{"key":"B67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"00718","DOI":"10.1183\/23120541.00718-2023","article-title":"AERIFY-1\/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD","volume":"10","author":"Rabe","year":"2024","journal-title":"ERJ Open Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/cpt.3147","article-title":"A randomized phase I study of the anti-interleukin-33 antibody tozorakimab in healthy adults and patients with chronic obstructive pulmonary disease","volume":"115","author":"Reid","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13287-020-02088-6","article-title":"Human umbilical cord mesenchymal stem cell-derived extracellular vesicles ameliorate airway inflammation in a rat model of chronic obstructive pulmonary disease (COPD)","volume":"12","author":"Ridzuan","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"8702","DOI":"10.3390\/ijms24108702","article-title":"The role of IL-33\/ST2 in COPD and its future as an antibody therapy","volume":"24","author":"Riera-Mart\u00ednez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"178716","DOI":"10.1016\/j.ejphar.2026.178716","article-title":"Targeting the Keap1-Nrf2 axis in COPD: comparative analysis of electrophilic and peptide-based Nrf2 activators in airway and immune cells","volume":"1019","author":"Roger","year":"2026","journal-title":"Eur. J. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2026.05.034","article-title":"Monoclonal antibodies targeting inflammatory pathways in COPD - evidence and opportunities","author":"Ross","year":"2026","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/sctm.17-0129","article-title":"Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine","volume":"6","author":"Samsonraj","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.3390\/ijms23094982","article-title":"The PDE4 inhibitor tanimilast restrains the tissue-damaging properties of human neutrophils","volume":"23","author":"Schioppa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12931-020-01512-y","article-title":"Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study","volume":"21","author":"Singh","year":"2020","journal-title":"Respir. Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"","journal-title":"Lancet Respir. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2402231","DOI":"10.1183\/13993003.02231-2024","article-title":"A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4","volume":"66","author":"Singh","year":"","journal-title":"Eur. Respir. J."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.jaci.2024.12.1086","article-title":"Clarification of the efficacy of tezepelumab in the phase 2a COURSE trial","volume":"155","author":"Singh","year":"","journal-title":"J. Allergy Clin. Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s40265-025-02188-8","article-title":"Chronic obstructive pulmonary disease (COPD): developments in pharmacological treatments","volume":"85","author":"Singh","year":"","journal-title":"Drugs"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2147\/IJN.S487097","article-title":"Bone marrow mesenchymal stem cells-derived exosomes inhibit apoptosis of pulmonary microvascular endothelial cells in COPD mice through miR-30b\/Wnt5a pathway","volume":"20","author":"Song","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"B86","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/15412555.2019.1682535","article-title":"Phase II study of single\/repeated doses of acumapimod (BCT197) to treat acute exacerbations of COPD","volume":"16","author":"Str\u00e2mbu","year":"2019","journal-title":"COPD"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2501403","DOI":"10.1183\/13993003.01403-2025","article-title":"Decoding the eosinophil connection: implications for precision treatment of emphysematous in COPD","volume":"66","author":"Sun","year":"2025","journal-title":"Eur. Respir. J."},{"key":"B88","doi-asserted-by":"publisher","first-page":"101309","DOI":"10.1016\/j.redox.2019.101309","article-title":"The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-\u03bab signaling","volume":"28","author":"Sun","year":"2020","journal-title":"Redox Biol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/ptr.7818","article-title":"Tussilagone ameliorates high-fat diet-induced hepatic steatosis by enhancing energy metabolism and antioxidant activity","volume":"38","author":"Sun","year":"2024","journal-title":"Phytother. Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.eclinm.2019.100249","article-title":"Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis","volume":"19","author":"Thompson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B92","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/19412711251396759","article-title":"Lung deposition of Tanimilast, an inhaled Phosphodiesterase-4 inhibitor, in patients with asthma or COPD, evaluated using functional respiratory imaging","volume":"39","author":"Tousi","year":"2025","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"B93","doi-asserted-by":"publisher","first-page":"OA1970","DOI":"10.1183\/13993003.congress-2015.OA1970","article-title":"Prospective phase 1 open clinical trial to study the safety of adipose derived mesenchymal stem cells (ADMSCs) in COPD and combined pulmonary fibrosis and emphysema (CPFE)","volume":"46","author":"Tzilas","year":"2015","journal-title":"Eur. Resp. J."},{"key":"B94","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/jcm11010056","article-title":"Soluble ST2 and all-cause mortality in patients with chronic obstructive pulmonary disease-A 10-year cohort study","volume":"11","author":"Urban","year":"2021","journal-title":"J. Clin. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"100124","DOI":"10.1016\/j.pharmr.2026.100124","article-title":"Regenerative therapeutics for chronic obstructive pulmonary disease","volume":"78","author":"van der Koog","year":"2026","journal-title":"Pharmacol. Rev."},{"key":"B96","doi-asserted-by":"publisher","first-page":"CD011600","DOI":"10.1002\/14651858.CD011600.pub3","article-title":"Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease","volume":"12","author":"van Geffen","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"B97","doi-asserted-by":"publisher","first-page":"14937","DOI":"10.1038\/ncomms14937","article-title":"Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma","volume":"8","author":"Verstraete","year":"2017","journal-title":"Nat. Commun."},{"key":"B98","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.freeradbiomed.2021.03.039","article-title":"Developing a novel strategy for COPD therapy by targeting Nrf2 and metabolism reprogramming simultaneously","volume":"169","author":"Wang","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.actbio.2025.07.068","article-title":"Inhalable nucleic acid therapeutics for chronic pulmonary disease: progress, challenges, and prospects","volume":"204","author":"Wang","year":"2025","journal-title":"Acta Biomater."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1378\/chest.12-2094","article-title":"A placebo-controlled, randomized trial of mesenchymal stem cells in COPD","volume":"143","author":"Weiss","year":"2013","journal-title":"Chest"},{"key":"B101","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12931-021-01734-8","article-title":"Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels","volume":"22","author":"Weiss","year":"2021","journal-title":"Respir. Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"114694","DOI":"10.1016\/j.jep.2021.114694","article-title":"The ethanol extract of flower buds of Tussilago farfara L. attenuates cigarette smoke-induced lung inflammation through regulating NLRP3 inflammasome, Nrf2, and NF-\u03baB","volume":"283","author":"Xu","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1474310","DOI":"10.3389\/fphar.2024.1474310","article-title":"Mitochondrial quality control: a pathophysiological mechanism and potential therapeutic target for chronic obstructive pulmonary disease","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jare.2025.07.019","article-title":"Tussilagone attenuated cigarette smoke-induced chronic obstructive pulmonary disease through regulating Nrf2 and NF-\u03baB\/NLRP3 inflammasome via directly targeting cysteine 434 of KEAP1","volume":"82","author":"Xu","year":"2026","journal-title":"J. Adv. Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molimm.2022.08.020","article-title":"Adipose-derived mesenchymal stem cells suppress ozone-mediated airway inflammation in a mouse model of chronic obstructive pulmonary disease","volume":"151","author":"Zhang","year":"2022","journal-title":"Mol. Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12890-025-03770-2","article-title":"MSCs regulate oxidative stress through the Nrf2 pathway to treat chronic obstructive pulmonary disease","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Pulm. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1911892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:43:29Z","timestamp":1787561009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1911892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":104,"alternative-id":["10.3389\/fphar.2026.1911892"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1911892","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1911892"}}